Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%82 Cash Ratio is 2.50 as of Mar. 2026, which is 17% above its 10-year median of 2.13. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 83.41% on this metric.
Surgical Science Sweden AB has a Cash Ratio of 2.50. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Surgical Science Sweden AB's Cash Ratio or its related term are showing as below:
SUSRF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.08 Med: 2.13 Max: 4.35
Current: 2.5
During the past 11 years, Surgical Science Sweden AB's highest Cash Ratio was 4.35. The lowest was 0.08. And the median was 2.13.
SUSRF's Cash Ratio is ranked better than 83.41% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.59
vs SUSRF: 2.50
Surgical Science Sweden AB (OTCPK:SUSRF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Surgical Science Sweden AB Cash Ratio Related Terms
Surgical Science Sweden AB Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Surgical Science Sweden AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Cash Ratio of 2.50 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Surgical Science Sweden AB and its competitors. This is 17% above median its historical median of 2.13. Over the past decade, Surgical Science Sweden AB's Cash Ratio has ranged from 0.08 to 4.35. According to the industry distribution chart, Surgical Science Sweden AB ranks #110 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 16.6%.
Is Surgical Science Sweden AB's Cash Ratio too high?
Surgical Science Sweden AB's current Cash Ratio of 2.50 is 17% above median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 4.35. The Healthcare Providers & Services industry median Cash Ratio is 0.59. Surgical Science Sweden AB's value of 2.50 is 323.7% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #110 out of 663 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Cash Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #110 out of 663 companies for Cash Ratio. This places Surgical Science Sweden AB in the top 17% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.59. Surgical Science Sweden AB's value of 2.50 is 323.7% above this benchmark. Historically, Surgical Science Sweden AB's own Cash Ratio has ranged from 0.08 to 4.35 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 0.59, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.59, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Cash Ratio of 2.50 is 323.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Cash Ratio is 2.50, which is 17% above median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.25, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current Cash Ratio is 2.50, which is 17% above median its 10-year median of 2.13 and 323.7% above the Healthcare Providers & Services industry median of 0.59. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Cash Ratio is 2.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.25.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Cash Ratio: 2.50 (17% above median its 10-year median of 2.13)
GF Value™: $14.25 vs. price of $4.00 (71.9% below fair value)
Industry Position: 323.7% above the Healthcare Providers & Services median (#110 of 663)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
